Brookline Capital Management Estimates KYMR Q2 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Brookline Capital Management issued their Q2 2025 EPS estimates for Kymera Therapeutics in a note issued to investors on Thursday, February 27th. Brookline Capital Management analyst L. Cann anticipates that the company will post earnings per share of ($0.97) for the quarter. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. Brookline Capital Management also issued estimates for Kymera Therapeutics’ Q3 2025 earnings at ($1.03) EPS.

A number of other analysts have also issued reports on the stock. Stephens restated an “overweight” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. BTIG Research assumed coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $60.00 price target for the company. Leerink Partners restated an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Friday, December 27th. Finally, HC Wainwright lifted their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Three research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $56.69.

Kymera Therapeutics Trading Up 1.7 %

Shares of NASDAQ:KYMR opened at $30.68 on Monday. The company has a fifty day simple moving average of $38.60 and a 200 day simple moving average of $43.56. The firm has a market cap of $1.99 billion, a PE ratio of -13.11 and a beta of 2.18. Kymera Therapeutics has a 12-month low of $29.07 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The firm had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors have recently bought and sold shares of KYMR. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock worth $114,000 after purchasing an additional 504 shares during the period. Harbor Capital Advisors Inc. raised its position in Kymera Therapeutics by 30.0% in the third quarter. Harbor Capital Advisors Inc. now owns 40,303 shares of the company’s stock worth $1,908,000 after acquiring an additional 9,292 shares in the last quarter. Natixis Advisors LLC bought a new stake in Kymera Therapeutics in the third quarter worth about $681,000. Thrivent Financial for Lutherans bought a new stake in Kymera Therapeutics in the third quarter worth about $313,000. Finally, Jennison Associates LLC raised its position in Kymera Therapeutics by 85.8% in the third quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock worth $37,754,000 after acquiring an additional 368,394 shares in the last quarter.

Insider Activity

In related news, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now owns 201,886 shares of the company’s stock, valued at $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ellen Chiniara sold 3,129 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total transaction of $130,635.75. Following the completion of the sale, the insider now directly owns 54,826 shares of the company’s stock, valued at $2,288,985.50. The trade was a 5.40 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 13,788 shares of company stock valued at $455,202. 15.82% of the stock is currently owned by company insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.